<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01035385</url>
  </required_header>
  <id_info>
    <org_study_id>VORP019</org_study_id>
    <nct_id>NCT01035385</nct_id>
  </id_info>
  <brief_title>Compare FOFLOX4 in Preoperative and Postoperative and Postoperative in Resectable Liver Metastasis Colorectal Cancer (MCC)</brief_title>
  <official_title>Phase III Study to Compared Preoperative and Postoperative With FOFLOX4 Chemotherapy and Postoperative With FOFLOX4 Chemotherapy in Patients With Resectable Liver Metastasis From Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, open-label, randomized ,controlled phase III study to compare
      preoperative and postoperative with FOFLOX4 chemotherapy and postoperative with FOFLOX4
      chemotherapy in patients with resectable liver metastasis from colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate the three-year progression free survival (PFS) advantage of FOLFOX4 in the
      treatment of resectable metastatic colorectal cancer.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival (PFS)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>response rate, incidence of postoperative complications,pathological response rate,R0 resection rate, 5-year overall survival,duration of disease control</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Liver Metastasis</condition>
  <arm_group>
    <arm_group_label>FOFLOX4,resectable liver metastasis from CRC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOFLOX4</intervention_name>
    <description>FOLFOX4:Oxaliplatin 85mg/m2 ivgtt d1 2hr calcium leucovorin:200mg/m2 ivgtt d1 d2 2hr fluorouracil:400mg/m2 iv d1 d2 fluorouracil:600mg/m2 civ d1 d2 22hr 2 weeks repeated one cycles</description>
    <arm_group_label>FOFLOX4,resectable liver metastasis from CRC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Resectable liver metastasis from colorectal cancer(the distance from the tumor lower
             edge to anal more than 12cm),no visible extrahepatic metastatic tumors. Curable by
             resection, as determined by a surgeon and imaging physicians. The minimum of the liver
             metastases needs ≥2cm. Patients can be recruited if meet the conditions about:

               -  Primary tumor had been removed of the metachronous liver metastasis patients and
                  no residue from the eyes or microscope.

               -  Primary tumor has been removed more than 1 month of the simultaneous liver
                  metastasis patients.

          2. Age of≥18 and ≤80

          3. ECOG≤2

          4. Signed written informed consent

        Exclusion Criteria:

          1. Peripheral neuropathy(CTC＞1)

          2. Had a neurological or mental disorders

          3. Active infection

          4. Allergy to Platinum-based and other drugs

          5. Other acute diseases including infection, heart-disease(CHF, stable or unstable
             angina)

          6. Pregnant or nursing patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Feng Lin, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Feng Lin, Dr</last_name>
    <phone>86-20-83827812-60910</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Li, Dr</last_name>
      <email>yongyongsamrt@yahoo.cn</email>
    </contact>
    <investigator>
      <last_name>Yong Li</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2009</study_first_submitted>
  <study_first_submitted_qc>December 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2009</study_first_posted>
  <last_update_submitted>December 17, 2009</last_update_submitted>
  <last_update_submitted_qc>December 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Feng Lin/Gastrointestinal Surgery</name_title>
    <organization>Guangdong General Hospital</organization>
  </responsible_party>
  <keyword>FOFLOX4</keyword>
  <keyword>resectable liver metastasis from colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

